Experimental immune cells show promise for COVID lung crisis
Disease control
Completed
This early-phase study tested a new cell therapy called agenT-797 in 20 adults hospitalized with moderate to severe COVID-19-related lung failure (ARDS). The main goal was to check safety and find the right dose. Researchers also looked at how long patients needed breathing machi…
Phase: PHASE1 • Sponsor: MiNK Therapeutics • Aim: Disease control
Last updated May 18, 2026 12:09 UTC